Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
Cetuximab
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "Cetuximab" in MCE Product Catalog:
55
Research Areas:
2
1
1 Cited Publications
Target:
Research Areas:
LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
Synonyms: IBI351; GFH925
Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .
Cat. No.: HY-P9S0008
Research Areas:
Cat. No.: HY-P99902
CAS No.: 1776942-10-9
Synonyms: FAP-IL2v; RO6874281; RG7461
Target:
Research Areas:
Cat. No.: HY-170704
CAS No.: 1480940-53-1
Target:
Research Areas:
DSPE-PEG2000-TCO is a click chemistry coupling partner. DSPE-PEG2000-TCO undergoes a reverse electron-demand Diels-Alder click reaction to form a covalent linkage with tetrazine-modified Cetuximab (HY-P9905). DSPE-PEG2000-TCO maintains the stability of lipid nanoparticles (LNPs) and has high mRNA encapsulation efficiency, which supports cellular uptake and mRNA transfection. DSPE-PEG2000-TCO is used to prepare EGFR-targeted and APN-targeted mRNA-loaded LNPs, mediating receptor-dependent endocytosis, mRNA delivery, and intestinal epithelial transcytosis .
Cat. No.: HY-D2060
CAS No.: 1188422-44-7
Cat. No.: HY-P99500
CAS No.: 2166339-33-7
Synonyms: RM-1929; Cetuximab-IRDye-700DX
Cat. No.: HY-P99324
CAS No.: 1646321-00-7
Synonyms: Anti-Human EGFR Recombinant Antibody; Cetuximab-GEX, GEXMab52201
Cat. No.: HY-136358
CAS No.: 1198408-39-7
Target:
Research Areas:
LDN-211904 is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .
Cat. No.: HY-164492
CAS No.: 1455031-68-1
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .
Cat. No.: HY-151048
CAS No.: 2140807-58-3
JBJ-07-149 is an inhibitor for EGFRL858R/T790M with an IC50 of 1.1 nM. JBJ-07-149 inhibits the proliferation of cell Ba/F3 with IC50 of 4.9 μM and 0.148 μM, without and with presence of Cetuximab (HY-P9905). JBJ-07-149 can be used as ligand for target protein in synthesis of DDC-01-163 (HY-139997) .
Cat. No.: HY-183553
CAS No.: 2874214-01-2
AUBE00 is an orally active, selective cyclic peptide pan-KRAS inhibitor. AUBE00 selectively binds to the OFF state of KRAS. AUBE00 exhibits anticancer activity against RAS wild-type colorectal cancer. The combination of AUBE00 with Cetuximab (HY-P9905) produces a synergistic antiproliferative effect .
Cat. No.: HY-107460R
CAS No.: 1198408-78-4
Target:
Research Areas:
LDN-211904 oxalate (Standard) is the analytical standard of LDN-211904 (oxalate) (HY-107460). This product is intended for research and analytical applications. LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
Cat. No.: HY-P991966
Cat. No.: HY-182018
CAS No.: 3126270-19-4
Research Areas:
ATR ligand 2-CO-Ph-COOH (Compound 39) is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for ATR (HY-182017) and a PROTAC linker, which recruits E3 ligases. can be used for synthesis of PROTAC ATR degrader-3 (HY-182016) .
Cat. No.: HY-P991984
Cat. No.: HY-181420A
CAS No.: 3029443-36-2
Target:
Research Areas:
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
